| Summary: | 碩士 === 中山醫學大學 === 生化暨生物科技研究所 === 97 === Background: Malignant tumors are at the top leading cause of death in Taiwan in the past decades. Angiogenesis is not only essential for tumor growth but is also implicated in invasion of the cancer cells into the circulation, and growth of dormant micro-metastases into frank metastatic lesions. Vascular endothelial growth factor (VEGF) plays an important role in angiogenesis as well as in solid tumors. It also has a role for VEGF in Malignant tumors; although has not been fully elucidated. This study will examine the VEGF secretary activity of malignant cells in the patients with prostate cancer or bladder cancer. The urine samples were obtained before, during and after treatment. The purposes of this study are to assay the VEGF value by ELISA method and its correlation with disease prognosis in various prostate cancer or bladder cancer; and to evaluate the VEGF concentrations between prostate cancer and bladder cancer.
Method: The urine samples were collected from 8 prostate cancer and 10 bladder cancer patients in this study. It also was compared to 11 normal samples. An enzyme-linked immunosorbent assay (ELISA) was used to quantify VEGF concentrations. Urine samples will be tested using a commercial Elisa system for VEGF, (R&D systems). Identification of VEGF tumor markers for malignant disease using Enzyme-Linked Immunosorbent Assay technologies. The differential VEGF concentrations were statistically analyzed using bioinformatic softwares.
Results: Our research samples were 61 specimens. The VEGF value was low in 11 cases of Negative control(2.60 pg/ml), no obvious auto-secretary activity of those cells. In 8 cases of prostatic carcinoma and 10 cases of
bladder cancer, the VEGF urine level were 96.80 pg/ml(p=0.001) and
271.13 pg/ml(p=0.012) respectively( Mann-Whitney test). High VEGF level decreased significantly during treatment . However, the cases were too small to had exact predict value (only 8 and 10 cases). Patients were with high VEGF auto-secretary activity and also had bad prognosis.
Conclusion: Although our study is a primary result, study cases are varied, but it still provide important information that VEGF has an important role in prostate cancer and bladder cancer. We will process further research of single and specific disease in the future to analyze the exact correlation of VEGF and malignant tumor diseases before, during and after treatment. The VEGF tumor-specific markers show great potential for the detection of the Malignant tumors.
|
|---|
